Desmopressin Incidents Indicate Need for Pharmacist Involvement in Development and Use of Monitoring Protocols
DOI:
https://doi.org/10.4212/cjhp.v61i3.58Abstract
Arecent ISMP Canada Safety Bulletin1 described safety concerns related to fluid management and desmopressin therapy. Here, we review selected information and excerpts from that bulletin that are highly relevant to hospital pharmacists. One of the key recommendations in the bulletin was to develop a protocol for monitoring patients who require desmopressin therapy. Development of standardized protocols and predefined order sets to assist in the management of selected patient groups is a highleverage strategy for enhancing consistency and incorporating best practices into patient care processes.Downloads
Downloads
Published
Issue
Section
License
Copyright © Canadian Society of Healthcare-Systems Pharmacy.
After publication of a manuscript in the CJHP, the authors of the manuscript must obtain written permission from the CSHP (publications@cshp.ca) before reproducing any text, figures, tables, or illustrations from the work in future works of their own. If a submitted manuscript is declined for publication in the CJHP, all said rights shall revert to the authors. Please note that any forms (e.g., preprinted orders and patient intake forms) used by a specific hospital or other health care facility and included as illustrative material with a manuscript are exempt from this copyright transfer. The CJHP will require a letter from the hospital or health care facility granting permission to publish the document(s).
